News Merck KGaA

Equities

MRK

DE0006599905

Market Closed - Xetra Other stock markets 11:35:20 2024-04-30 am EDT			5-day change	1st Jan Change
149 ^EUR	-0.67%		+0.85%	+3.37%

10:28am	MERCK KGAA : Jefferies keeps its Buy rating	ZD
Apr. 29	Habeck's 'pharma trip' - industry sees structural problems	DP

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MERCK KGAA : Jefferies keeps its Buy rating	04:28am	ZD
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
Ex-dividend day for final dividend	Apr. 28	FA
Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board	Apr. 26	DP
Transcript : Merck KGaA - Shareholder/Analyst Call	Apr. 26
Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Merck KGaA Starts Building EUR300 Million Life Science Research Center in Germany	Apr. 25	MT
Scholz visits Merck and Family Business Days	Apr. 24	DP
US competitor Danaher boosts Merck KGaA and Sartorius	Apr. 23	DP
MERCK KGAA : Barclays reiterates its Buy rating	Apr. 19	ZD
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Agronomics Portfolio Company Mosa Meat Raises EUR40 Million to Beef Up Production	Apr. 17	MT
Merck KGaA Rolls Out New Genetic Stability Assay Platform	Apr. 16	MT
MERCK : A peer group tidy up	Apr. 13
Merck Announces Change of Managing Director of Merck Life Science in India	Apr. 09	CI
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 05	AQ
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment	Apr. 04	AQ
Caris Life Sciences Announces Partnership with Merck KGaA to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 04	CI
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

MERCK : A peer group tidy up

April 13, 2024 at 04:06 pm EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST